Cargando…

Pediatric psoriasis treated with apremilast

Detalles Bibliográficos
Autor principal:	Smith, Rebecca L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809471/ https://www.ncbi.nlm.nih.gov/pubmed/27051839 http://dx.doi.org/10.1016/j.jdcr.2015.12.005

Ejemplares similares

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Comorbid psoriasis-bipolar disorder successfully treated with apremilast: much more than a mere coincidence?
por: Uvais, N A, et al.
Publicado: (2020)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report
por: Shah, Bela J, et al.
Publicado: (2019)

Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review
por: Brunasso, Alexandra Maria Giovanna, et al.
Publicado: (2021)

Refractory erythema annulare centrifugum treated with apremilast
por: Lee, Michelle S., et al.
Publicado: (2021)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
por: De, Abhishek, et al.
Publicado: (2019)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
por: Jeon, Caleb, et al.
Publicado: (2017)

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
por: MALARA, Giovanna, et al.
Publicado: (2021)

Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
por: Lanna, Caterina, et al.
Publicado: (2019)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
por: Wang, Wen-Ming, et al.
Publicado: (2020)

Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report
por: Zarbafian, Misha, et al.
Publicado: (2019)

Repigmentation of Tenacious Vitiligo on Apremilast
por: Huff, Sara B., et al.
Publicado: (2017)

Apremilast in Refractory Alopecia Areata
por: Estébanez, Andrea, et al.
Publicado: (2019)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Apremilast for treatment of recalcitrant aphthous stomatitis
por: Schibler, Fabian, et al.
Publicado: (2017)

Apremilast as an adjuvant therapy for calcinosis cutis
por: Qiblawi, Sultan H., et al.
Publicado: (2019)

Treatment of a perforating dermatosis with apremilast
por: McMichael, Josette, et al.
Publicado: (2021)

Treatment of pyoderma gangrenosum with apremilast monotherapy
por: Bordeaux, Zachary A., et al.
Publicado: (2022)

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
por: Jonak, Constanze, et al.
Publicado: (2023)

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Successful treatment of refractory folliculitis decalvans with apremilast
por: Fässler, Mirjam, et al.
Publicado: (2020)

Crushed apremilast for the treatment of oral lichen planus
por: Kim-Lim, Penelope, et al.
Publicado: (2023)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
por: Tanaka, Masayuki, et al.
Publicado: (2021)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7g740qdokkb59v1tbgakeh8u5f